Alzheimer’s prevention that doesn’t pay

Oh boy. Buckle up, because I’ve got a whopper of a tale to tell you…

Researchers in Vancouver recently completed studies that indicated ibuprofen — one of the country’s most popular over-the-counter pain medicines — might be able to prevent Alzheimer’s disease, if you start taking it early enough.

This ranks right up there among the craziest things I’ve ever heard, considering ibuprofen is a non-steroidal anti-inflammatory drugs (NSAID). And if you’re a longtime reader of mine, you know how I feel about NSAIDs.

Countless studies show that they increase the risk of heart attack, stroke, and sudden death — just to name a few of their potentially deadly side effects.

So claiming one of these poisons is the solution to a problem that has stumped mainstream medicine for years seems like a bit of a stretch if you ask me.

But when you dig a little deeper into the details of this discovery, the real reason behind this absurd conclusion becomes clear…

This research was spearheaded by a husband-and-wife neuroscientist team that also happen to head the Vancouver-based company Aurin Biotech. (A noteworthy detail to keep in mind.) Their lab is famous for its long history of research on neuro-inflammatory and neurodegenerative diseases — and on Alzheimer’s disease, in particular.

A couple of years back, they announced the development of a new saliva test, which measures concentrations of amyloid beta protein 42 (Abeta42). According to the study, this protein can supposedly diagnose and predict future onset of Alzheimer’s.

The test itself is genius in its simplicity: Most people produce the same amount of Abeta42, without variation due to gender or age. But if you’ve got an Alzheimer’s diagnosis in your future, your rate of Abeta42 production will be up to three times higher than the general population.

You see, Abeta42 builds up in the brain, where it triggers the neuron-destroying inflammation characteristic of Alzheimer’s disease. But any organ in your body can generate this peptide.

So, these scientists argue, patients with high Abeta42 should start taking ibuprofen daily, starting at age 55, which is a good decade before most cases of Alzheimer’s are diagnosed.

They call this discovery a “game changer.” But you know what I call it? A way for their biotech company to make a fortune selling their Abeta42 test. After all, who wouldn’t want to take this test?

But the real question I have is — why ibuprofen?! A known liver toxin, and a cause of gastritis, ulcers, and a list of other side effects a mile long. They’re not even suggesting other NSAIDs, much less alternative approaches to controlling inflammation.

But that doesn’t mean those alternative approaches don’t exist.

In fact, you can tame inflammation in a number of ways. Including with my A-List Diet (which was just released in paperback on Amazon). Not to mention a host of other strategies, all of which you’ll find in my recent Drug-Free Protocol for Reversing Alzheimer’s and Dementia.

If you’d like to learn more about this all-natural plan to protect and restore your memory, strengthen your focus, and build a bigger, brighter brain (all while reducing inflammation), click here.

Not to detract from the value of Abeta42, but this study is only a “game-changer” for people who haven’t been paying attention. Control inflammation, and you control your health. But you absolutely don’t need ibuprofen to do it.